SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

ALX Oncology Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Expect to report safety and early efficacy data from the Phase 1 dose-escalation study of ALX2004 in

ALXO

Related stories